July 2, 2015 : Episode 1

MM-398 Priority Review, CPX-351 in AML, CAR T-cell Collaboration, and More

Video

Related Videos
Jorge J. Castillo, MD,
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Alessandra Ferrajoli, MD
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Related Content
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
Walter Klemp of Moleculin

EMA Grants Orphan Drug Designation to Annamycin in AML

April 18th 2024
Article
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024
Article